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Background
Although widely used, the current evidence for the efficacy of
antidepressant and anti-anxiety medications for people with
autism spectrum disorder (ASD) is limited and conflicting.
Aims
We carried out a systematic review and meta-analysis of ran-
domised controlled trials that assessed the effectiveness of
these medications in people with ASD.
Method
We searched the following databases: Cochrane Library,
Medline, EMBASE, CINAHL, PsycINFO, ERIC, DARE and
ClinicalTrials.gov. Additionally, we hand-searched 11 relevant
journals. We used the Cochrane risk-of-bias tool and Jadad score
to assess the quality of each included study. We carried out a
meta-analysis using a random effects model.
Results
We included 15 randomised controlled trials (13 on antidepres-
sants and two on anti-anxiety medications) for a total of 958
people with ASD. Data showed contradictory findings among the
studies, with larger studies mostly showing a non-significant
difference in outcomes between the treatment and the placebo
groups. Meta-analysis of pooled Yale-Brown Obsessive
Compulsive Scale and Clinical Global Impression Scale data from
nine studies (60%) did not show any statistically significant inter-
group difference on either of the outcome measures. The
adverse effects reported were mild and, in most studies, their
rates did not show any significant inter-group difference.
Conclusions
Given the methodological flaws in the most included studies and
contradictory findings, it is difficult to draw any definitive con-
clusion about the effectiveness of either antidepressant or anti-
anxiety medications to treat either ASD core symptoms or
associated behaviours. Robust, large-scale, randomised con-
trolled trials are needed to address this issue.
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Autism spectrum disorder (ASD) is a neurodevelopmental dis-
order that starts in early childhood and often continues into
adulthood. The condition is characterised by persistent deficits
in social communication and social interaction across multiple
contexts, and restricted and repetitive patterns of behaviour
(RRB), interests or activities.1 The condition affects 1 in every
160 people.2
Psychiatric comorbidities in ASD
ASD is associated with considerable comorbidities with both
other neurodevelopmental disorders such as intellectual and
developmental disabilities (IDD) and attention-deficit hyper-
activity disorder (ADHD), and functional psychiatric disorders
such as psychosis, depression and anxiety.1 One population-
based German study reported depressive disorder in 8.3%,
anxiety disorder in 11.1%, psychotic disorder in 1.6% and
sleep disorders in 4.9% of 1124 people (aged 0–24 years) with
ASD.3 In another community-based study of 112 children
(aged 10–14 years), the overall rate of anxiety and phobic disor-
ders was reported in 41.9% (social anxiety in 29.2%), ADHD in
28.2% and oppositional defiant disorder or conduct disorder in
30% of the cohort.4
The prevalence of psychotropic medication use in ASD
A systematic review by Jobski et al5 included 47 studies of the preva-
lence of psychotropic medication use in people with ASD (N > 300
000) published between 1976 and 2012. The overall median rate of
psychotropic use was 45.7%, which was higher among adults
(61.5%) than children (41.9%). Polypharmacy of psychotropic use
was reported on average among 23% of people with ASD. The most
commonly used psychotropics were antipsychotics (median 18.1%),
antidepressants (median 17.2%) and psychostimulants (median
16.6%). The use of anti-anxiety medication is reported among 6.8%
of children and adolescents.3 Psychotropic use in this population
seems to have increased over the years.3,6 A longitudinal study
between 1998 and 2005 found that 57% of adolescents and adults
with ASD were taking one or more psychotropic medications at the
beginning of the study, which increased to 64% by the end of the
study (P < 0.05).7
A systematic review of the efficacy of tricyclic
antidepressants in ASD
Hurwitz et al8 included only two small, crossover randomised con-
trolled trials (RCTs) on clomipramine with 12 children, and 31 chil-
dren and adults with ASD respectively, in a Cochrane review of the
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effectiveness of tricyclic antidepressants. One study showed the
superiority of clomipramine over placebo and the other study did
not show any significant inter-group difference. Another small
RCT used tianeptine, which is now withdrawn from the market
because of its potential addictive effect. The authors concluded
that ‘clinicians considering the use of tricyclic antidepressants
need to be aware of the limited and conflicting evidence of effect
and the side effect profile when discussing this treatment option
with people who have ASD and their carers. Further research is
required before tricyclic antidepressants can be recommended for
treatment of individuals with ASD’.
A systematic review of the efficacy of selective
serotonin reuptake inhibitors in ASD
Williams et al9 published a Cochrane review on the effectiveness of
selective serotonin reuptake inhibitors (SSRIs) in people with ASD.
They included nine RCTs involving children (n = 5) and adults
(n = 4), assessing the effect of SSRIs on ASD core and associated
symptoms: three on fluoxetine, two on fluvoxamine, two on fenflur-
amine (fenfluramine is withdrawn from themarket now) and two on
citalopram. Most studies included a small number of participants,
but one parallel-design RCT of >100 children showed no superiority
of citalopram over placebo. Of the four adult studies, one was based
on unpublished data and another included only six participants. The
other two small studies (with 30 and 37 participants, respectively)
showed significant improvement in some behaviour in the medica-
tion groups (one study on fluoxetine and one study on fluvoxamine)
compared with the placebo. The authors concluded that ‘there is no
evidence of effect of SSRIs in children and emerging evidence of
harm. There is limited evidence of the effectiveness of SSRIs in
adults from small studies in which risk of bias is unclear’.
Justification for the current systematic review
No systematic review exists on the efficacy of anti-anxiety medica-
tion for people with ASD, although many SSRIs are used to treat
anxiety symptoms. One systematic review on the treatment of
anxiety in people with ASD found nine studies on cognitive–behav-
iour therapy and four open-label studies involving fluvoxamine,
citalopram and buspirone.10 As several studies on antidepressants
have been published since the review by Williams et al,9 and there
is no published systematic review on anti-anxiety medications, we
decided to carry out a systematic review and meta-analysis based
solely on RCTs (as non-RCTs are likely to produce bias) of anti-
depressant (both old and new generation) and anti-anxiety (includ-
ing benzodiazepines, buspirone and beta-blockers) medications for
people with ASD for any indication (ASD core symptoms, including
communication and language issues; associated behaviours, includ-
ing agitation and aggression; and/or psychiatric disorders such as
depression and anxiety).
Method
Our objective was to determine the effectiveness of antidepressant
and anti-anxietymedications in people with ASD for any indication.
The study was registered with International Prospective Register of
Systematic Reviews (PROSPERO; identifier CRD42020210708) on
16 October 2020.
Search strategy
We followed PROSPERO guidelines11 and the Preferred Reporting
Items for Systematic Review and Meta-Analysis Protocols
(PRISMA-P) checklist12 to develop our protocol and search
strategy. We searched the following databases for English-language
publications between January 1985 and October 2020: Medline,
EMBASE, PsycINFO, Cochrane Library, CINAHL, ERIC, DARE
and ClinicalTrials.gov. Also, we cross-referenced pertinent reviews
and articles. We hand-searched for relevant articles published
between January 1990 and October 2020 in relevant journals in the
field of ASD (Journal of Autism and Developmental Disorders, Autism
Research, Journal of Autism Spectrum Disorder), IDD (Journal of
Intellectual Disability Research, Journal of Applied Research in
Intellectual Disabilities,Research inDevelopmental Disabilities) and psy-
chopharmacology (Psychopharmacology, Neuropsychopharmacology,
International Journal of Neuropsychopharmacology, Journal of
Clinical Psychopharmacology, Human Psychopharmacology, Journal
of Child and Adolescent Psychopharmacology), using relevant search
terms. Search terms are described in Supplementary Appendix 1
available at https://doi.org/10.1192/bjo.2021.1003, and included
terms like RCTs, depression, anxiety and anxiety disorder.
Selection criteria
The titles, abstracts and full papers were screened independently by
two authors (M.R. and J.S.), using pre-piloted eligibility criteria
(Supplementary Appendix 2) designed as per Cochrane Library13
and PROSPERO11 guidelines. All RCTs in ASD involving antide-
pressants and anti-anxiety medications were included. The list of
excluded studies with reasons for exclusion is provided in
Supplementary Appendix 3.
Participants
Participants had a diagnosis of an ASD, defined using standardised
criteria such as the DSM or ICD, or based on a clinical assessment.
The diagnosis may or may not have been made with a standardised
diagnostic instrument. No age limit was applied. Studies that
included people with IDD were included if the participants also
had a confirmed diagnosis of ASD. We excluded any RCT that
included less than ten participants, in line with our previous
reviews.14–17
Intervention
We included studies of both new- and old-generation antidepres-
sants, including SSRIs, serotonin–noradrenaline reuptake inhibitor,
tricyclics, any other types of antidepressants and any type of anti-
anxiety medications such as benzodiazepines, buspirone, beta-
blockers and pregabalin, regardless of dosage used or frequency of
administration.
Design and comparators
Only RCTs that evaluated the effectiveness of antidepressants and
anti-anxiety medications on people with ASD of any age (including
children, adolescents and adults) were included in this review. The
control treatment could be a placebo or another medication.
Outcome measures
Any standardised validated outcome measure to assess mental state,
including symptoms of any psychiatric illness such as depression
and anxiety; ASD core symptoms such as language and communi-
cation impairment and RRB; and any other associated behaviours
such as agitation, aggression, irritability, hyperactivity and any
other problem behaviour.
Selection process
Any discrepancy in scoring was resolved by discussion and, if neces-
sary, arbitration by a third author (S.D.). Data were organised with
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Mendeley (Version 1.19.8 for Windows, Elsevier, Amsterdam, the
Netherlands; see https://www. mendeley.com/download-desktop-
new/)Reference Manager.18
Data extraction
Data were extracted independently by two authors (R.L. and M.M.),
using a proforma modified from the Cochrane template19
(Supplementary Appendix 4). As people with ASD are likely to be
more sensitive to psychotropic medication, we have taken note of
the adverse effects described in the included studies20–34 and
presented the findings in Table 1.
Quality assessment of included studies
The quality of the included RCTs was assessed independently by
two authors (R.L. and M.M.), using the Cochrane risk-of-bias
tool35 (Supplementary Appendix 5) and the Jadad score.36 Any dis-
crepancy in scores was resolved by discussion between the authors,
with arbitration from a third author (B.L.). Overall findings were
presented in a narrative format, but a meta-analysis was also
carried out where possible.
Data synthesis
A narrative synthesis of the findings is provided in Table 1.20–34
Where there were more than one studies, a meta-analysis was
carried out. A random-effects odds ratio or standardised mean dif-
ference with 95% confidence interval meta-analysis was performed,
depending on the type of data gathered. Heterogeneity was tested
with the χ2-test and I2-statistic test of heterogeneity. If there was
substantial heterogeneity (I2 > 50%) as per the Cochrane guide, a
further sensitivity analysis was carried out.37
Meta-analysis
We pooled data for meta-analysis only from those RCTs that pre-
sented data with the same outcome measure. A standardised
mean difference was calculated for those studies that presented
means and s.d. for scores based on an outcome measure in the
two groups.37 RevMan version 5.3 (The Nordic Cochrane Centre,
The Cochrane Collaboration, Copenhagen, Denmark; see www.
training.cochrane.org) software for Windows 10 was used for
random-effects meta-analysis, because of the heterogeneity.
Meta-bias(es)
Funnel plots38 were drawn, and an Egger’s value was calculated39 to
assess publication bias (Supplementary Appendices 6 and7).
Confidence in cumulative estimate
The quality of evidence was assessed across the risk-of-bias domains
of consistency, directness, precision and publication bias. Any
ambiguous studies that were deemed of low quality were excluded
from the review. The PRISMA-P checklist was completed, and the
overall quality of the systematic review and the meta-analysis was
assessed with the A Measurement Tool to Assess Systematic
Reviews 2 (AMSTAR 2) checklist (Supplementary Appendix 8).40
No ethical approval was necessary for this review as no individual
patient-related data were collected or analysed.
Results
Search findings
Initially, we identified 2306 titles from the literature search and
hand search of the relevant journals, and ultimately included 15
studies in this review (see Fig. 1). Data were first extracted on the
10 December 2020. We included 13 studies on antidepressants
(four on fluoxetine, two on clomipramine, two on fluvoxamine,
two on venlafaxine, one on citalopram, one on sertraline and one
on agomelatine) and two on the anti-anxiety medication buspirone.
We did not find any RCT on the long-term use of beta-blockers or
benzodiazepines.
Description of the study population
These studies included 958 participants in total. There was a male
preponderance among the participants, reflecting the male prepon-
derance among people with ASD. Seven RCTs (53.85%) on antide-
pressants included children and adolescents only (age ranged from
2 to 18 years), four RCTs (30.76%) included adults only and another
two RCTs (15.38%) included both children and adults (age ranged
from 6 to 36 years). All participants (adults) in two studies (15.38%)
had IDD, in eight studies (61.53%) a high proportion had IDD and
IQ was not reported in three studies (23.07%). Both RCTs on anti-
anxiety medications included children and adolescents only (age
starting from 2 years), and none reported participant IQ.
Information on the inclusion and exclusion criteria for each
study, along with comorbidities and funding source, is provided
in Supplementary Appendix 9.
Outcome measures used in the included studies
We did not find any RCT that used outcome measures for anxiety
and depression. Instead, these RCTs assessed the effect of the
medications on ASD core symptoms such as RRB, and other
associated behaviours such as irritability, hyperactivity and
aggression. The two most common outcome measures used were
the ASD core symptom of RRB measured by the Yale-Brown
Obsessive Compulsive Scale (YBOCS)41 and Children-YBOCS
(C-YBOCS),42 and the Clinical Global Impression-Improvement
(CGI-I) Scale (National Institute of Mental Health).43 Both scales
were used in seven RCTs (46.66%). Some of the other outcomemea-
sures included the Aberrant Behaviour Checklist-Community,44
Repetitive Behaviours Scale,45 Children’s Global Assessment
Scale46 and modified Children’s Psychiatric Rating Scale.47
A narrative synthesis of the data
Old generation of antidepressants
Clomipramine. The findings of the included studies are sum-
marised in Table 1.20–34 Two RCTs on old-generation antidepres-
sant tricyclics were on clomipramine, both of which were small
crossover trials (n = 24 and 36);24,25 one compared clomipramine
with desipramine and placebo,24 and the other with haloperidol
and placebo.25 One found clomipramine to be marginally signifi-
cantly better than placebo in treating ASD core symptoms like
RRB,24 but the other one did not show any significant inter-group
difference.25
New generation of antidepressants, including SSRIs
Fluoxetine. Among the new generation of antidepressants, most
RCTs were on SSRIs. Four RCTs were on fluoxetine, one of which
was a small crossover trial of 45 children and the rest were paral-
lel-design RCTs involving 158 children, 146 children and 37
adults, respectively.26–29 Of the two larger RCTs, one26 showed no
statistically significant inter-group difference on RRB, but the
authors felt the overly cautious dosing regime and the
short follow-up may have prevented the therapeutic effect of fluox-
etine. The other large parallel-design RCT29 initially showed a sig-
nificantly better outcome of fluoxetine compared with the
placebo, but the study evidenced a high drop-out rate (25%), the
Antidepressant and anti‐anxiety medications for autism spectrum disorder
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Table 1 Summary findings




diagnosis) Dose of medications
Participants (N, Age
(mean ± s.d.), gender,
IQ (mean ± s.d.),
Intervention, FU Outcome measures used Findings, Jadad score Comments
Agomelatine
Ballester et al, 201920 Crossover
(DSM-V)
Agomelatine (25 mg/day) N = 23







TST, TiB, SoL, Number of
awakenings during TiB, Wake
after sleep onset, Sleep
efficiency
Only night TST significantly increased (mean
83 min) during agomelatine treatment
(abnormal TST among 50% participants pre-
treatment v. 16% post agomelatine
treatment) (P = 0.016). No significant change
in other sleep parameters.
The authors reported only mild and
transient adverse events associated with
the agomelatine treatment.
Jadad = 4
Small sample size risking type II error.
The outcome is not directly related to
ASD core symptoms, although sleep
problem is common in ASD. Only one
sleep parameter has shown
improvement.
Buspirone





Buspirone 5 mg twice daily













ADOS-RRB, ABC, VABS, RBS,
SPS, C-YBOCS-PDD, CGI, Leiter
Parent-Report
A non-significant intergroup difference in
the primary outcome ADOS-CTS. RRB score
as per CYBOCS-PDD showed a significant
difference from baseline to FU (P = 0.03) in
2.5 mg twice daily dose but not in the 5 mg
twice daily dose or the placebo group.
There was no significant intergroup
difference in the rate of adverse events.
Jadad = 5
Reasonable sample size but
contradictory findings based on






Buspirone 10 mg/day (<40 kg)
or 20 mg/day (>40 kg)
N = 40 (34 completed)





FU: 4 and 8 weeks
ABC-Irritability subscale Thirteen (81.2%) in the buspirone group and
seven (38.9%) in the placebo group showed
a >30% decline in irritability score, although
total irritability score improved significantly
from the baseline score in both groups (both
P < 0.001).
No major adverse events are reported. The
most common adverse events associated
with buspirone treatment were increased




Small sample size risking a type II error.
Citalopram




Citalopram 10 mg/5 mL,
2.5 mg-20 mg/day
N = 149 (123
completed)
Age: 5–17 years (9.4 ±
3.1 years)
Male: 86%





C-YBOCS-PDD total score +
RRB, CGI-I, RBS, ABC
No significant intergroup difference in C-
YBOCS-PDD, RRB, and CGI-I scores.
Citalopram group showed more adverse
effects such as increased energy,
impulsiveness, decreased concentration,
hyperactivity, stereotypy, diarrhoea,
insomnia, and dry skin or pruritus.
Jadad = 5
A large sample is likely to have given
adequate power to the study but the
overall dropout rate maybe a bit high.























25 mg/day-250 mg/day (or 5
mg/kg/day)
N = 28 (24 completed)
Age: 6–23 years (10.4
± 4.1 years)
Male: 62.5%







Modified CPRS OCD subscale,
CGI
Clomipramine was superior to both placebo
(P ≤ 0.001) and desipramine (P ≤ 0.005) in
improving CPRS subscales and CGI scores.
There was no effect of age, gender, IQ level,
and dose of clomipramine on the outcome.
The authors reported minor adverse effects
in all three groups without any significant
intergroup difference.
Jadad = 3
Small sample size risking a type II error.
A short washout period may have
caused a carry-over effect on long-
standing behaviours.
















Global ASD measures CARS,
ESRS, DOTES, ABC- subscales
Clomipramine did not show any superiority
over placebo, but haloperidol did (P < 0.05)
on the global measure of autistic symptoms,
and ABC-irritability, hyperactivity, and
stereotype subscale scores.
Adverse events associated with
clomipramine included fatigue (n = 4),
tremors (n = 2), tachycardia (n = 1), insomnia
(n = 1), diaphoresis (n = 1), nausea or
vomiting (n = 1), and decreased appetite (n
= 1). Four of them also showed problem
behaviour.
Jadad = 4
Small sample size risking a type II error.
A short washout period may have
caused a carry-over effect on long-
standing behaviours. A complicated
study design has made the
interpretation of findings difficult.
Fluoxetine














CYBOCS-PDD total + RRB
score, CGI, CSQ
No significant intergroup difference in any of
the outcome measures. ‘Much improved’
and ‘very much improved’ in 23% of
fluoxetine and 34% placebo group as per
CGI-I scores.
The rate of adverse effects was similar in the
two groups and both groups showed a high
rate of activation (fluoxetine: 42%, placebo:
45%).
Jadad = 5
A large sample may have given
adequate power, but the authors
suggested that a low starting dose may
have prevented a therapeutic effect.
Hollander et al, 200527 Crossover
(DSM-IV,
ADI-R, ADOS)
Fluoxetine 2.5 mg/day to
0.8 mg/kg/day
N = 45 (39 completed)
Age: 5–17 years
Male: 76.9%





C-YBOCS RRB score, Autism
global symptoms, CGI
Moderate to large effect size on C-YBOCS
RRB score (z = −2.075, SE = 0.407, P = 0.038).
No effect on CGI, speech, social interaction.
There was no significant intergroup
difference in the rate of adverse effects. The
fluoxetine group reported a numerically
lower rate of insomnia, anxiety, urinary
incontinence, and mild weight gain but a
higher rate of sedation, agitation, diarrhoea,
and anorexia when compared with the
placebo group.
Jadad = 3
Small sample size risking a type II error.
A short washout period may have
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diagnosis) Dose of medications
Participants (N, Age
(mean ± s.d.), gender,
IQ (mean ± s.d.),
Intervention, FU Outcome measures used Findings, Jadad score Comments
Hollander et al, 201228 Parallel design
(DSM-IV,
ADI-R, ADOS)
Fluoxetine 10 mg/day starting
dose to maximum of
80 mg/day
N = 37 (34 completed)
Age: 18–60 years
(34.31 ± 14.26 years)
Male: 69%





YBOCS RRB score, CGI, ABC,
HAM-D
Fluoxetine was superior to placebo on
YBOCS RRB score (F = 9.24, df = 1, 30.7, P =
0.005, d = 0.53).
CGI improvement in obsessive-compulsive
symptoms (score 2 or less): 50% in the
fluoxetine group v. 8% in the placebo group
(P = 0.03).
HAM-D scores were well under the
threshold for a diagnosis of depressive
disorder in both groups.
A statistical comparison of intergroup
adverse effects was not possible. In the
fluoxetine group, 1.4 adverse effects per
patient were reported compared with 0.6 in
the placebo group. Adverse events
associated with the fluoxetine treatment
were mild to moderate and included bad
dreams (n = 3), mild insomnia (n = 3), mild
dry mouth (n = 3), and headaches (n = 3).
There was no statistically significant
intergroup difference in the rates of suicidal
ideation between the fluoxetine (6%) and
the placebo group (0%) (P = 1.00). No one in
either group reported suicidal gestures or
attempts.
Jadad = 3
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4 or 8 mg/day for the first
week (4 mg if <40 kg; 8 mg if
≥40 kg) maximum dose was
20 mg/day (participants <40
kg) or
30 mg/day (participants ≥40
kg).
N = 146 (109
completed)
Age: 7.5–18 years






C-YBOCS-PDD, RBS, ABC, CGI The mean C-YBOCS-PDD score decreased in
the fluoxetine group by 3.72 points (95% CI,
−4.85 to −2.60) and in the placebo group by
2.53 points (95% CI, −3.86 to −1.19). The
between-group mean difference at follow
up was −2.01 (95% CI, −3.77 to −0.25; P =
0.03) (adjusted for stratification factors), and
in the prespecified model with further
adjustment, it was −1.17 (95% CI, −3.01 to
0.67; P = 0.21). The multiple imputation
analysis did not show any statistically
significant intergroup difference (mean
difference, −1.82; 95%CI, −3.71 to 0.06; P =
0.06).
The rate of commonly observed adverse
effects such as irritability, mood
disturbance, nausea, vomiting, and sleep
disorders did not show any significant
intergroup difference (fluoxetine, 45%, the
total number of events 2.5 (s.d. ± 1.6) and
placebo,
48%, the total number of events
2.6 (s.d. ± 2.1).
Jadad = 4
Initial analysis showed the superiority
of fluoxetine over placebo, but this
difference was not maintained when
baseline imbalance in outcome scores
between two arms was adjusted for.
Also, the confidence interval of the
scores included a minimally clinically
important difference. High dropout rate
(25%)
Fluvoxamine
McDougle et al, 199630 Parallel design
(DSM-III-R, ICD-10)
Fluvoxamine: 50 mg/day,
increased every 3 or 4 days to
a maximum of 300 mg/day as
tolerated
N = 30 (all completed)
Age: 18–53 years
(30.1 ± 7.7 years)
Male: 90%










A significantly higher proportion of the
fluvoxamine group (53%) was reported to be
responders to treatment compared with the
placebo group (0%). Fluvoxamine was
superior in improving repetitive thoughts
and behaviour (P < 0.001), problem
behaviour (P < 0.001), aggression (P < 0.03),
some aspects of social relatedness (P <
0.04), and language usage (P < 0.008). Age,
the severity of autism symptoms, and the
level of IQ did not influence the treatment
response.
Other than mild sedation and nausea in a
few cases, fluvoxamine was well tolerated.
No one reported dyskinesias, seizures,
electrocardiograph change, anticholinergic,
or adverse cardiovascular events.
Jadad = 3
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diagnosis) Dose of medications
Participants (N, Age
(mean ± s.d.), gender,
IQ (mean ± s.d.),
Intervention, FU Outcome measures used Findings, Jadad score Comments
Sugie et al, 200531 A crossover study
in the context of
genetic evaluation
(DSM-IV)
Fluvoxamine 1–3 mg/kg body
weight/day
N = 19 (18 completed)
Age: 3 years - 8 years 5







BAS, CGI Fluvoxamine showed a statistically
significant improvement in two (flighty eye
movements and delayed or peculiar or
inappropriate speech) of the 20 BAS items
compared with the placebo.
Fluvoxamine did not show any significant
adverse effects other than transient nausea
and hyperactivity.
Jadad = 5
Small sample size risking a type II error.
No adjustment is made for multiple
comparisons to avoid any type I error.
Sertraline
Potter et al, 201932 Parallel design
(DSM-IV, ADOS)
Sertraline (20 mg/mL), under
four years: 2.5 mg/day (0.125
mL); four years or older: 5 mg/
day (0.25 mL).











raw score and age equivalent
combined score), CGI, PVET,
VABS-II, ABC-C, PAS-R, SRS,
SPM-P, PLS-5, Visual Analog
Scale
ITT analysis did not show any significant
intergroup difference in any outcome
measure.
No statistically significant intergroup
difference in the rate of adverse effects. No
sertraline-associated serious adverse event
was reported.
Jadad = 4
Small sample size risking a type II error.
Venlafaxine




introduced or continued with
dose adjustment as necessary
N = 13
Age : venlafaxine : 18–









ABC, BPI, CGI Reduction in
usual doses of zuclopenthixol
or clonazepam, Simpson-
Angus Rating Scale
Univariate analyses showed that the
symptom of irritability improved in the entire
sample (P = 0.061), although no difference
was observed between the venlafaxine and
the placebo group. No significant decrease
in hyperactivity/noncompliance was
observed during the study. Global
improvement was observed in 33% of
participants treated with venlafaxine and in
71% of participants in the placebo group (P
= 0.29). Decreased cumulative doses of
clonazepam and zuclopenthixol were
required for the venlafaxine group.
Multivariate analyses (principal component
analyses) with at least three combinations of
variables showed that the two populations
could be clearly separated (P < 0.05).
A few adverse effects in the venlafaxine
group included excessive salivation, slight
elbow stiffness, mild finger tremor, and
head dropping. No comparative data for the
placebo group is provided by the authors.
Jadad = 3
Small sample size. Very complicated
design involving the use of additional
medications, which makes
interpretation of the findings difficult.
Different results are shown depending




















Venlafaxine: 30 mg/day N = 15 (14 completed)
Age: 5.2–11.7 years
(7.1 ± 3 years)
Male: 100%




CGAS, CGI, ABC, Modified
CPRS
No statistically significant intergroup
difference in the clinician’s rating of
videotaped behaviour according to CPRS,
CGAS, and CGI. Statistically significant better
improvement in ABC sub scores of irritability
(P = 0.04), inadequate eye contact (P =
0.042), hyperactivity (P = 0.035), and lethargy
(P = 0.043) according to the teacher’s rating
during the venlafaxine treatment compared
with the placebo phase.
Adverse effects such as increased thirst,
drowsiness, sleep disturbance, sadness,
dizziness, irritability, decreased activity have
been reported in the venlafaxine treatment
group but without providing the number of
participants affected or any comparative
data in the placebo phase.
Jadad = 3
Very small all-male clinic sample, so the
generalisability of the findings is
questionable.
ABC, Aberrant Behaviour Checklist; ABC-C, Aberrant Behavior Checklist-Community version; ADI-R, Autism Diagnostic Interview-Revised; ADOS-CTS, Autism Diagnostic Observation Schedule-Composite Total Score; ADOS-SA, Autism Diagnostic Observation Schedule-Social
Affect; ADOS-RRB, Autism Diagnostic Observation Schedule-Restricted and Repetitive Behaviour; ASD, Autism Spectrum Disorder; BAS, Behaviour Assessment Scale; BPI, Behaviour Problems Inventory; CARS, Childhood Autism Rating Scale; CGAS, Children’s Global
Assessment Scale; CGI, Clinical Global Impressions Scale; CGI-I, Clinical Global Impressions-Improvement Scale; CI, Confidence Interval, CPRS OCD subscale, Comprehensive Psychological Rating Scale Obsessive Behaviour Disorder subscale; CSQ, Caregiver Strain
Questionnaire; C-YBOCS-PDD, Children’s Yale-Brown Obsessive Compulsive Scale-Modified for Pervasive Developmental Disorders; df, degree of freedom; DOTES, Dosage Treatment Emergent Symptom Scale; DSM-V, Diagnostic and Statistical Manual of Mental Disorders, 5th
Edition; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revision; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition-Revised; DQ,
Development Quotient; ESRS, Extrapyramidal Symptom Rating Scale; FU, Follow-up; ICD-10, International Classification of Diseases 10th Revision; HAM-D, Hamilton Depression Rating Scale; IDD, Intellectual and Developmental Disability; ITT, Intention to Treat; IQ, Intelligence
Quotient; MSEL, Mullen Scales of Early Learning; N, number; PAS-R, Preschool Anxiety Scale-Revised; PLS-5, Preschool Language Scales, 5th Edition; PVET, Passive-Viewing Eye Tracking Task; RBS, Repetitive Behavior Scale; RRB, Restrictive Repetitive Behaviors; SD, Standard
deviation; SE: Standard Error; SoL, Sleep onset Latency; SPM-P, Sensory ProcessingMeasure-Preschool; SPS, Sensory Profile Scale; SRS, Social Responsiveness Scale; TiB, Time in Bed; TST, Total Sleep Time; VABS-II, Vineland-Adaptive Behaviour Scale-II (maladaptive behaviors);
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significant difference was not sustained when baseline imbalance
between the two groups was adjusted for, and the confidence inter-
val of the difference in the outcome score included minimal clinic-
ally effective difference. The smaller crossover RCT27 and parallel-
design28 RCT showed a significantly better efficacy of fluoxetine
over placebo.
Fluvoxamine. In two small trials on fluvoxamine, one involved 19
children in a crossover trial31 and the other involved 30 adults in a
parallel-design RCT.30 The parallel-design study30 showed a statis-
tically significant better effect of fluvoxamine on RRB and social
communication and aggression. The crossover study31 was carried
out in the context of a genetic study, which showed a significant
improvement in two of the 20 items (10%) in a behaviour scale
devised by the authors in the fluoxetine compared with the
placebo phase.
Citalopram. One large-scale, parallel-design RCT involving 149 chil-
dren23 did not show any significant inter-group difference between the
citalopram and the placebo group in RRB and CGI-I score.
Venlafaxine. There were two small RCTs involving venlafaxine:
one included 14male children in a crossover study34 and found con-
flicting evidence depending on the outcome measure used, and
another study included3313 children in a parallel-design RCT and
did not find any significant inter-group difference in efficacy.
Sertraline. A parallel-design study involving 58 children did not
show any significant inter-group difference in the efficacy
between sertraline and the placebo.32
Agomelatine. A crossover trial of 23 adults showed improvement
in night total sleep time but no other sleep parameters during ago-
melatine treatment, but not in the placebo phase.20 No ASD core
symptoms were assessed in this study.
We did not find any RCT involving paroxetine, escitalopram,
mirtazapine, duloxetine or vortioxetine.
Anti-anxiety medication
Buspirone. We found two parallel-design RCTs on buspirone,
involving 40 and 166 children.21,22 The larger study21 did not show
any significant inter-group difference in the primary outcome
measure of Autism Diagnostic Observation Schedule composite
score48 at the 24-week follow-up. For RRB, 5 mg twice daily dose
and placebo did not show any significant change from baseline, but
2.5 mg twice daily dose showed a significant improvement. The
smaller study22 showed a significant improvement in the Aberrant
Behaviour Checklist irritability subscale score44 in the buspirone
compared with the placebo group.
Adverse effects
In most studies, there was no statistically significant inter-group dif-
ference in the rate of medication-related adverse events, except for a
large study of citalopram23 and a small study of clomipramine (see
Table 1).25 In the large study, citalopram was more significantly
associated with adverse events, such as hyperactivity, decreased con-
centration, impulsiveness and stereotype, compared with the
placebo.23 In the other study, clomipramine25 was more signifi-
cantly associated with problem behaviour, fatigue, tremor and
cardiac problems, compared with the placebo.
Quality of the included papers
The Cochrane risk-of-bias analysis showed seven out of 15 studies
(46.66%) scored a high risk in at least one item, of whom four
(26.66%) showed a high risk in two items (see Fig. 2). Ten out of
15 studies (66.66%) received a Jaded score of <5.
Meta-analysis (RRB and CGI scores)
Using YBOCS-/C-YBOCS-based RRB scores, we managed to pool
data for meta-analysis from seven (46.66%) out of 15 RCTs (four
on fluoxetine, one on fluvoxamine, one on citalopram and one on
buspirone) (see Fig. 3). Similarly, using the CGI-I score, we were
able to pool data from seven RCTs, all of which were on antidepres-
sants (46.66%) (four on fluoxetine, one on citalopram, one on ser-
traline and one on venlafaxine) (see Fig. 4). Altogether, it was
possible to pool data from nine (60%) RCTs. Fluoxetine and
citalopram did not show any significant inter-group difference,
but the fluvoxamine score was significantly better than the
placebo. Buspirone data could not be pooled together as there was
only one study that used RRB as an outcome, which showed a
significantly better effect of the medication when the two different
doses were combined (i.e. 5 mg and 2.5 mg twice daily dose, respect-
ively). The overall pooled data on antidepressants and anti-anxiety
medication did not show any statistically significant inter-group
difference, although the heterogeneity was high at I2 = 71 (see
Fig. 3). Neither the individual antidepressants nor the pooled
data on CGI-I showed any statistically significant inter-group
difference, and the heterogeneity was low at I2 = 0 (see Fig. 4).
Funnel plots did not show any publication bias for either
forest plot, and Egger’s test scores were P = 0.42 for the YBOCS
and P = 0.87 for the CGI-I forest plot, respectively. When the
studies with a high risk of bias were removed from themeta-analysis,




Our systematic review found 13 RCTs involving antidepressants
clomipramine, fluvoxamine, fluoxetine, citalopram, sertraline, ven-
lafaxine and agomelatine, and two on the anti-anxiety medication
buspirone. The evidence for the efficacy of old-generation tricyclic
antidepressants in improving ASD symptoms and associated behav-
iour is lacking, based on only two small crossover trials with contra-
dictory results. Tricyclics are not recommended for use because of
their anticholinergic and cardiac adverse effects, and the risk of
fatality associated with overdose. As for the new generation of anti-
depressants (SSRIs and serotonin–noradrenaline reuptake inhibi-
tors), the evidence is non-conclusive. Only three studies included
>100 participants (158 and 146 children for fluoxetine, and 149 chil-
dren for citalopram respectively). The citalopram study did not
show a statistically significant inter-group difference. Of the two
large fluoxetine studies, one did not show any superiority over
placebo, and although the other one showed the superiority of flu-
oxetine in the initial analysis, this difference disappeared when
adjusted for baseline inter-group imbalance and the confidence
intervals were taken into account. This study also had a high
drop-out rate.
The rest of the smaller studies showed contradictory results,
with some showing superiority of the medication over placebo
and the others not. Only one of the two RCTs on buspirone included
>100 participants (166 children), which did not show any inter-
group difference in the primary outcome of Autism Diagnostic
Observation Schedule-Composite Score but showed a statistically
Deb et al
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significant improvement in RRB only with the smaller daily dose
(2.5 mg twice daily), but not the higher dose (5 mg twice daily).
No RCT was found on any other anti-anxiety medications such as
benzodiazepines or beta-blockers (the only RCTs on beta-blockers
were on a single-dose administration; see Supplementary
Appendix 3). Benzodiazepines are not recommended for long-
term use because of their effect on cognition, paradoxical emergence
of aggression, tolerance and addiction. Similarly, the administration
of high doses of beta-blockers risks adverse effects such as lowering
of blood pressure and respiratory failure.
Meta-analysis showed no statistically significant inter-group
difference between antidepressants and the placebo. These findings
are consistent with the previous Cochrane review.9 However, we
included additional RCTs that were not included in the previous
Cochrane review.9
We have also carried out a systematic review on the RCTs of
anti-anxiety medication on people with ASD, which was not done
before.
Methodological issues
Most studies were on children, but some included data on adults with
ASD, and no specific age effect was observable from the data presented
in Table 1.20–34 Of the 15 RCTs, six (40%) used a crossover design.
Crossover design may not be ideal to assess long-standing behaviour
outcomes, particularly if the washout period is relatively short, as is
the case in the included studies. Several studies recruited participants
with ASDwho also had IDD, but often did not present data separately
on those participants. Therefore, it is difficult to assess the influence of
IQ on the outcome.
The overall quantity and quality of the RCTs are, at best, poor.
However, our meta-analysis mitigates that to some extent. Based on
the currently available weak and contradictory evidence, our sys-
tematic review can neither support nor refute the use of antidepres-
sant and anti-anxiety medications for the treatment of ASD core
symptoms such as RRB, impaired social communication or asso-
ciated behaviour such as aggression, irritability and agitation,
Titles identified through database
searching





















Additional titles identified through
other sources
(n = 2)  

















(n =   9) 
Reasons for exclusion
Neuroimaging study, no clinical
outcome data (n = 2) 
Single-dose administration of
propranolol (n = 4)  
Antidepressant was tianeptine,
which is withdrawn from the
market (n = 1)  
Effect of tryptophan depletion
rather than any medication (n = 1)
Children with fragile X syndrome
were included but data on children
with ASD were incomplete (n = 1)  
Fig. 1 Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow chart of paper selection. ASD, autism spectrum
disorder.
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despite their widespread use in this population. However, this sys-
tematic review does not answer the question of whether antidepres-
sants and anti-anxiety medications are effective in treating
depression and anxiety in people with ASD, as we did not find
any RCTs involving these medications for the treatment of depres-
sion and anxiety in the ASD population. In fact, most included
RCTs excluded participants with a comorbid psychiatric disorder
(see Supplementary Appendix 9). Therefore, the evidence for this
has to be extrapolated from studies done on individuals without
ASD. Although the RCTs included in our review did not show
any significant inter-group difference in the rate of adverse effects
in most studies, these medications have known adverse effects.
Therefore, the clinicians considering the use of these medications
for people with ASD, particularly to treat ASD core symptoms
and associated behaviours, should carefully weigh up the supporting
evidence (or lack of it) and the potential for adverse effects, which
may be more pronounced in people with ASD.
Information on funding was not available for three studies, but
the available data shows that apart from possibly one exception, the








































































































































Ballester et al, 201920
Carminati et al, 201633
Chugani et al, 201621
Ghanizadeh and Ayoobzadehshirazi, 201522
Gordon et al, 199324
Herscu et al, 202026
Hollander et al, 200527
Hollander et al, 201228
King et al, 200923
McDougle et al, 199630
Niederhofer, 200434
Potter et al, 201932
Reddihough et al, 201929
Remington et al, 200125
Sugie et al, 200531
Fig. 2 Cochrane risk-of-bias summary scores.20–34
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1.1.1 Fluoxetine






IV, random, 95% CIMeans.d. s.d.Total Total Weight IV, random, 95% CI
Herscu et al, 202026 13.5 3.3 78 12.4 3.6 80 17.7% 0.32 [0.00−0.63]
11.77 3.2 20 12.38 2.4 19 11.0% −0.21 [−0.84 to 0.42]
10.48 3.92 21 11.15 3.05 13 10.0% −0.18 [−0.87 to 0.51]
9.02 4.84 75 10.89 4.29 71 17.4% −0.41 [−0.73 to −0.08]
13.1 3.7 73 13.1 3.2 76 17.5% 0.00 [−0.32 to 0.32]
73 76 17.5% 0.00 [−0.32 to 0.32]
13.7 9.1 15 21.9 6.7 15 8.9% −1.00 [−0.76 to 0.23]
10.8982 0.6301 109 11.2 0.6 57 17.4% −0.48 [−0.81 to −0.16]
15 15 8.9% −1.00 [−1.76 to 0.23]
109 57 17.4% −0.48 [−0.81 to −0.16]
391 331 100.0% −0.23 [−0.53 to 0.07]
−0.10 [−0.52, to −0.31]
Hollander et al, 200527
Hollander et al, 201228
Reddihough et al, 201929
Subtotal (95% Cl) 194 183 56.1%
Heterogeneity: Tau2 = 0.12; Chi2 = 10.15, d.f. = 3 (P = 0.02); I2 = 70%
Test for overall effect: Z = 0.48 (P = 0.63)
1.1.2 Citalopram
King et al, 200923
Subtotal (95% Cl)
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.00)
1.1.3 Fluvoxamine
McDougle et al, 199630
Subtotal (95% Cl)
Heterogeneity: not applicable
Test for overall effect: Z = 2.56 (P = 0.01)
1.1.4 Buspirone
Chugani et al, 201621
Subtotal (95% Cl)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.003)
Total (95% Cl)
Heterogeneity: Tau2 = 0.10; Chi2 = 20.43, d.f. = 6 (P = 0.002); I2 = 71%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Chi2 = 8.50, d.f. = 3 (P = 0.04), I2 = 64.7%
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Carminati et al, 201633
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.86)
King et al, 200923
Potter et al, 201932
Subtotal (95% Cl)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% Cl)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.13, d.f. = 6 (P = 0.66); I2 = 0%
Test for overall effect: Z = 1.75 (P = 0.08)
Test for subgroup differences: Chi2 = 2.85, d.f. = 3 (P =  0.42), I2 = 0%
−0.29 [−0.68 to 0.09]
−0.52 [−1.16 to 0.12]
−0.29191 −0.19731 21.2%
−0.522 0.3264 7.7%
−0.39 [−1.09 to 0.32]−0.3855 0.3598 6.4%
−0.14 [−0.47 to 0.18]−0.1434 0.1658 30.0%
0.38 [−0.72 to 1.48]0.38 0.5635 2.6%
−0.03 [−0.41 to 0.34]−0.03297 0.191411 22.5%
0.08 [−0.49 to 0.66]0.0846 0.2935 9.6%
−4 −2 0 2 4
−0.26 [−0.48 to −0.04]65.3%
−0.26 [−0.72 to 1.48]2.6%
−0.03 [−0.41 to 0.34]22.5%
0.08 [−0.49 to 0.66]9.6%
−0.16 [−0.34 to 0.02]100.0%
Favours medication Favours placebo
Fig. 4 Forest plot based on the Clinical Global Impression-Improvement Scale (CGI-I) pooled data.
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(see Supplementary Appendix 9). Therefore, the findings from these
studies could be considered independent and not influenced by the
funding organisations.
Weakness
Several drawbacks have to be considered when interpreting the data
of this systematic review. Different studies used different outcome
measures, which produced heterogeneity when the findings were
combined. As a result, we could only pool data for meta-analysis
from those studies that used the same outcome measure, such as
the YBOCS/C-YOBCS and CGI-I, which were reported in only
nine (60%) of the 15 RCTs. Although the meta-analysis of CGI-I
data showed no heterogeneity, the forest plot involving data from
YBOCS/C-YBOCS scores showed high heterogeneity. Another
major problem is the small sample size in most studies. For
example, only four studies (26.7%) included >100 participants.
This makes the findings from most of these studies difficult to gen-
eralise. Almost half of the studies have also shown at least one area
of a high risk of bias according to the Cochrane risk-of-bias
assessment.
Strengths
Our review used a very stringent methodology, including hand-
searching of 12 relevant journals, and should have captured the
most relevant RCTs. This is reflected in the full score of the
AMSTAR 2, apart from one noncritical item for not including
grey literature. It is still possible to miss relevant papers and we
only included English-language papers. Another problem is that
studies with positive findings tend to be published more often
than studies with a negative finding, creating a publication bias.
However, the funnel plots in our review did not show any major
publication bias. Another strength of this review is that it is regis-
tered on PROSPERO, so the study protocol is publicly available
(www.crd.york.ac.uk/prospero).
Future direction
The overmedication of people with ASD is a cause for major
concern, and NHS England launched a major initiative in 2016,
called STOMP (STopping Over Medication of People with learning
disability, autism or both), to address this issue.49 Therefore, it is
very important to use medication for people with ASD that is
based on strong evidence. Often, people with ASD and/or IDD
are excluded from major intervention studies, as recruiting and
obtaining informed consent is perceived as difficult. This problem
can be addressed by developing appropriate ASD- and IDD-specific
communication means to convey the research-related information
to the participants, and using accessible easy-read versions of
consent forms. It is important to include both people with ASD
and their family/carers in any future research for successful recruit-
ment. Also, the research question has to be tightly defined. For
example, the current review did not find any study of antidepres-
sants specifically for the treatment of depression or anxiety disor-
ders. Similarly, no study was detected on the efficacy of anti-
anxiety medications in treating anxiety disorders. Future research
should learn from previous research as elaborated in our review,
and have a multicentre, wider consensus-based approach, with
very stringent scientific design.
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